| Literature DB >> 27190688 |
Ayyanampakkam Pandurangan Nambi1, Badal Rathi2, Kavitha S1, Ghanshyam Dudhatra2, Hamsa S Yamini1, Abid Ali Bhat1.
Abstract
The efficacy of a novel topical combination of fipronil 9.8% (w/v) and (S)-methoprene 8.8% (w/v) (Fiprofort® Plus) was tested against ticks and fleas in naturally infested dogs. A total of fifty dogs were allocated in the study with ticks infestation (n = 35) and fleas infestation (n = 15). On day 0, thirty-five tick and fifteen flea infested dogs received the test formulation, a combination of fipronil 9.8% (w/v) and (S)-methoprene 8.8% (w/v) spot-on solution. Ticks and flea counts were taken on days 0 (pretreatment) and 3, 7, 14, 21, 28, and 35 after treatment. Blood samples were collected for evaluation of haematological parameters on days 0 (pretreatment) and 7, 21, and 35 after treatment. All the adult ticks and fleas collected were identified as Rhipicephalus sanguineus and Ctenocephalides felis, respectively. The efficacy of spot-on formulation against ticks was 34.00% (day 3), 53.14% (day 7), 62.71% (day 14), 65.48% (day 21), 59.80% (day 28), and 58.82% (day 35), whereas against fleas it was 38.00% (day 3), 64.34% (day 7), 89.67% (day 14), 95.40% (day 21), 100.00% (day 28), and 100.00% (day 35). Haematological parameters for ticks and fleas infested dogs were statistically nonsignificant as compared to control. The combination of fipronil and (S)-methoprene eliminated the existing ticks and fleas infestation and prevented the dogs from flea and tick infestation for four weeks.Entities:
Year: 2016 PMID: 27190688 PMCID: PMC4852104 DOI: 10.1155/2016/7174685
Source DB: PubMed Journal: Scientifica (Cairo) ISSN: 2090-908X
Efficacy and speed of kill of Fiprofort Plus spot-on against ticks during 35 days of the study.
| Study day | Count | Percentage | % efficacy | ||
|---|---|---|---|---|---|
| Live | Dead | Live | Dead | ||
| 0 | 195 | 0 | 100.00 | 0.00 | 0.00 |
| 3 | 128 | 66 | 66.00 | 34.00 | 34.00 |
| 7 | 91 | 103 | 46.94 | 53.06 | 53.14 |
| 14 | 73 | 122 | 37.36 | 62.64 | 62.71 |
| 21 | 67 | 127 | 34.58 | 65.42 | 65.48 |
| 28 | 78 | 116 | 40.27 | 59.73 | 59.80 |
| 35 | 80 | 114 | 41.25 | 58.75 | 58.82 |
Efficacy (%) = 100 × (M − M )/M , where M is the mean of live ticks on the control group and M is the mean of live ticks on the treatment groups.
Day 0 is control (untreated).
Figure 1Efficacy (%) of Fiprofort Plus spot-on application against ticks and fleas during 35 days of the study.
Efficacy and speed of kill of Fiprofort Plus spot-on against fleas during 35 days of the study.
| Study day | Count | Percentage | % efficacy | ||
|---|---|---|---|---|---|
| Live | Dead | Live | Dead | ||
| 0 | 37 | 0 | 100.00 | 0.00 | 0.00 |
| 3 | 23 | 23.56 | 62.00 | 38.00 | 38.00 |
| 7 | 13 | 22.94 | 35.66 | 64.34 | 64.34 |
| 14 | 4 | 9.26 | 10.33 | 89.67 | 89.67 |
| 21 | 2 | 4.39 | 4.60 | 95.40 | 95.40 |
| 28 | 0 | 0 | 0.00 | 100.00 | 100.00 |
| 35 | 0 | 0 | 0.00 | 100.00 | 100.00 |
Efficacy (%) = 100 × (M − M )/M , where M is the mean of live fleas on the control group and M is the mean of live fleas on the treatment groups.
Day 0 is control (untreated).
Haematological profiles of tick infested dogs before and after Fiprofort Plus application.
| Study day | Haemoglobin (g/dL) | PCV (%) | RBC (×106/cmm) | WBC (×103/cmm) | Platelet (×105/cmm) |
|---|---|---|---|---|---|
| 0 | 13.31 ± 0.28 | 39.44 ± 0.92 | 5.69 ± 0.15 | 13.06 ± 2.6 | 2.26 ± 0.92 |
| 7 | 13.21 ± 0.29 | 38.76 ± 0.97 | 5.62 ± 0.14 | 13.39 ± 3.6 | 2.49 ± 1.57 |
| 21 | 13.32 ± 0.29 | 39.06 ± 0.93 | 5.61 ± 0.15 | 15.68 ± 3.5 | 2.39 ± 1.24 |
| 35 | 13.1 ± 0.44 | 39.04 ± 0.92 | 5.64 ± 0.14 | 15.66 ± 1.5 | 2.38 ± 0.96 |
|
| |||||
| Significance | 0.682NS | 0.65NS | 0.64NS | 0.583NS | 0.214NS |
NS: statistically nonsignificant (P > 0.05).
Day 0 is control (untreated).
Haematological profiles of flea infested dogs before and after Fiprofort Plus application.
| Study day | Haemoglobin (g/dL) | PCV (%) | RBC (×106/cmm) | WBC (×103/cmm) | Platelet (×105/cmm) |
|---|---|---|---|---|---|
| 0 | 12.81 ± 0.16 | 36.91 ± 0.75 | 5.48 ± 0.14 | 15.52 ± 5.18 | 2.55 ± 0.15 |
| 7 | 12.47 ± 0.23 | 34.59 ± 0.84 | 5.20 ± 0.12 | 10.13 ± 0.45 | 3.06 ± 0.35 |
| 21 | 12.79 ± 0.25 | 36.48 ± 0.67 | 5.23 ± 0.11 | 8.87 ± 0.42 | 2.73 ± 0.33 |
| 35 | 13.05 ± 0.21 | 36.91 ± 1.34 | 5.34 ± 0.12 | 11.92 ± 1.58 | 3.03 ± 0.28 |
|
| |||||
| Significance | 0.100NS | 0.120NS | 0.140NS | 0.347NS | 0.215NS |
NS: statistically nonsignificant (P > 0.05).
Day 0 is control (untreated).